{
  "ticker": "STRO",
  "company_name": "Sutro Biopharma, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07227168",
      "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer",
      "start_date": "2025-11-07",
      "completion_date": "2028-04",
      "enrollment": 0,
      "sponsor": "Sutro Biopharma, Inc."
    },
    {
      "nct_id": "NCT03748186",
      "title": "Study of STRO-002, an Anti-Folate Receptor Alpha (FolR\u03b1) Antibody Drug Conjugate in Ovarian & Endometrial Cancers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma",
      "start_date": "2019-02-01",
      "completion_date": "2024-06-04",
      "enrollment": 0,
      "sponsor": "Sutro Biopharma, Inc."
    },
    {
      "nct_id": "NCT06555263",
      "title": "Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-small Cell Stage IV, Lung Cancer, Non-small Cell",
      "start_date": "2024-08-21",
      "completion_date": "2025-05-01",
      "enrollment": 0,
      "sponsor": "Sutro Biopharma, Inc."
    },
    {
      "nct_id": "NCT05200364",
      "title": "A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma",
      "start_date": "2022-03-22",
      "completion_date": "2025-06-01",
      "enrollment": 0,
      "sponsor": "Sutro Biopharma, Inc."
    },
    {
      "nct_id": "NCT05870748",
      "title": "REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1",
      "status": "TERMINATED",
      "phase": "PHASE2, PHASE3",
      "condition": "Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer",
      "start_date": "2023-07-12",
      "completion_date": "2025-08-26",
      "enrollment": 0,
      "sponsor": "Sutro Biopharma, Inc."
    },
    {
      "nct_id": "NCT03424603",
      "title": "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Indolent Lymphoma, B Cells--Tumors",
      "start_date": "2018-02-22",
      "completion_date": "2024-03-15",
      "enrollment": 0,
      "sponsor": "Sutro Biopharma, Inc."
    },
    {
      "nct_id": "NCT06679582",
      "title": "Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Acute Myeloid Leukemia (AML)",
      "start_date": "2024-12-04",
      "completion_date": "2025-06-01",
      "enrollment": 0,
      "sponsor": "Sutro Biopharma, Inc."
    },
    {
      "nct_id": "NCT06238687",
      "title": "A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Neoplasm Malignant",
      "start_date": "2023-11-08",
      "completion_date": "2027-12-30",
      "enrollment": 0,
      "sponsor": "Tasly Pharmaceutical Group Co., Ltd"
    }
  ],
  "summary": {
    "total_trials": 8,
    "by_phase": {
      "PHASE1": 4,
      "PHASE2": 1,
      "PHASE2, PHASE3": 1,
      "PHASE1, PHASE2": 2
    },
    "by_status": {
      "RECRUITING": 2,
      "COMPLETED": 2,
      "WITHDRAWN": 1,
      "TERMINATED": 3
    },
    "active_trials": 2,
    "completed_trials": 2,
    "conditions": [
      "Acute Myeloid Leukemia (AML)",
      "B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Indolent Lymphoma, B Cells--Tumors",
      "Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer",
      "Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-small Cell Stage IV, Lung Cancer, Non-small Cell",
      "Neoplasm Malignant",
      "Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer",
      "Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma",
      "Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:07.698425",
    "search_query": "Sutro Biopharma, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Sutro+Biopharma,+Inc."
  }
}